Addressing the challenges of novel therapies in rare diseases with mechanistic perspectives: Missed opportunities or the way forward?
- PMID: 35446442
- DOI: 10.1111/bcp.15350
Addressing the challenges of novel therapies in rare diseases with mechanistic perspectives: Missed opportunities or the way forward?
References
REFERENCES
-
- Micallef J, Blin O. Orphan drug designation in Europe: a booster for the research and development of drugs in rare diseases. Therapie. 2020 Apr;75(2):133-139. doi:10.1016/j.therap.2020.02.003
-
- Kesselheim AS, Solomon DH. Incentives for drug development-the curious case of colchicine. N Engl J Med. 2010;362(22):2045-2047. doi:10.1056/NEJMp1003126
-
- Groft SC, Posada de la Paz M. Preparing for the future of rare diseases. Adv Exp Med Biol. 2017;1031:641-648. doi:10.1007/978-3-319-67144-4_34
-
- Forbes TA, Brown BD, Lai C. Therapeutic RNA interference: a novel approach to the treatment of primary hyperoxaluria. Br J Clin Pharmacol. 2022;88(6):2525-2538. doi:10.1111/bcp.14925
-
- Poddighe D, Romano M, Garcia-Bournissen F, Demirkaya E. Conventional and novel therapeutic options in children with familial Mediterranean fever: a rare autoinflammatory disease. Br J Clin Pharmacol. 2022;88(6):2484-2499. doi:10.1111/bcp.15149
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
